Official source Data mirrored from Centers for Medicare & Medicaid Services Open Payments · General Payments · as published 2026-01-23 View official record Methodology

Covered recipient · General Payments record

ROBERTO LUCERO

Allopathic & Osteopathic Physicians Family Medicine

NPI
1144607193
CMS profile
5695870
Location
WINTER PARK, FL

General Payments · PY2018–2024

$1,155.46

  • Reported across 45 records
  • CMS publication 2026-01-23

Latest program year · PY2024

$309.08

13 records · 0 disputed

Financial relationships do not necessarily indicate an improper relationship; the data is open to interpretation.

How these totals are calculated
  • The total is the sum of the General Payments records CMS published for the labeled program year(s), exactly as published. Nothing is estimated, weighted, or combined across categories.
  • General Payments only. Research and Ownership/Investment are separate datasets and are never summed with these figures; amounts are kept separate per program year.
  • Featured-page threshold (a presentation gate, not a judgment): records>=3 OR total>=100 (all years).
  • Methodology & Data — sourcing, labeling, and limitations.

By nature of payment

PY2024 · sorted by reported total

Nature of paymentAmountRecords
Food and Beverage $309.08 13

By paying entity

PY2024 · sorted by reported total

Paying entityAmountRecords
Lilly USA, LLC $59.40 3
Acerta Pharma LLC $52.72 2
Exact Sciences Corporation $48.14 2
ABBVIE INC. $32.55 1
Dynavax Technologies Corporation $30.68 1
Biogen, Inc. $28.03 1
GlaxoSmithKline, LLC. $22.27 1
SHIELD THERAPEUTICS INC $20.54 1
Novo Nordisk AS $14.75 1

By program year

All program years on this page · sorted by year

Program yearAmountRecords
PY2018 $130.10 6
PY2019 $85.75 4
PY2020 $32.71 2
PY2021 $74.09 3
PY2022 $110.03 1
PY2023 $413.70 16
PY2024 $309.08 13

Payment records · PY2024 (13)

Sorted by paying entity, then date · as published by CMS

Program year 2024 201820192020202120222023 Record-level detail is published for PY2024; earlier years are summarised in “By program year”.
Paying entity Amount Date Nature of payment Dispute status Published Record ID Source
ABBVIE INC. $32.55 12/02/2024 Food and Beverage Undisputed 01/23/2026 1104908906 CMS
AstraZeneca Pharmaceuticals LP $29.25 08/28/2024 Food and Beverage Undisputed 01/23/2026 1104612718 CMS
AstraZeneca Pharmaceuticals LP $23.47 11/18/2024 Food and Beverage Undisputed 01/23/2026 1104255301 CMS
Biogen, Inc. $28.03 12/04/2024 Food and Beverage Undisputed 01/23/2026 1104844804 CMS
Dynavax Technologies Corporation $30.68 07/26/2024 Food and Beverage Undisputed 01/23/2026 1082150051 CMS
Exact Sciences Corporation $23.52 07/15/2024 Food and Beverage Undisputed 01/23/2026 1114764586 CMS
Exact Sciences Corporation $24.62 10/07/2024 Food and Beverage Undisputed 01/23/2026 1114764592 CMS
GlaxoSmithKline, LLC. $22.27 10/02/2024 Food and Beverage Undisputed 01/23/2026 1116366945 CMS
Lilly USA, LLC $21.73 07/17/2024 Food and Beverage Undisputed 01/23/2026 1135337702 CMS
Lilly USA, LLC $15.67 09/12/2024 Food and Beverage Undisputed 01/23/2026 1135337698 CMS
Lilly USA, LLC $22.00 11/21/2024 Food and Beverage Undisputed 01/23/2026 1135337706 CMS
Novo Nordisk Inc $14.75 08/09/2024 Food and Beverage Undisputed 01/23/2026 1097454347 CMS
SHIELD THERAPEUTICS INC $20.54 12/20/2024 Food and Beverage Undisputed 01/23/2026 1150158591 CMS

Source & provenance

Dataset
CMS Open Payments — General Payments
Publisher of source data
Centers for Medicare & Medicaid Services
CMS publication date
2026-01-23
Program years on this page
2018, 2019, 2020, 2021, 2022, 2023, 2024
Source files
Dataset page · Bulk file · PY2018 , PY2019 , PY2020 , PY2021 , PY2022 , PY2023 , PY2024
Generated from
OP_DTL_GNRL_PGYR2024_P01232026_01102026.csv

One page per canonical provider; split Profile_IDs are merged via Associated_Covered_Recipient_Profile_ID_1/_2 from the Covered Recipient Profile Supplement.

Corrections to the substance of a record route to CMS through its review-and-dispute process; errors in how this site mirrors or displays a record route to us. Both paths are described in Methodology & Data.